产品
编 号：F159404
分子式：C83H117N23O18S2
分子量：1789.09
分子式：C83H117N23O18S2
分子量：1789.09
产品类型
规格
价格
是否有货
结构图
CAS No: 1427001-89-5
产品详情
生物活性：
AMY-101 (Cp40), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation.
体内研究：
AMY-101 can improve the periodontal condition of NHPs with natural chronic periodontitis.AMY-101 can induce a long-lasting anti-inflammatory effect.AMY-101 (4 mg/kg bodyweight, subcutaneous injection. once per 24 hr for a total of 28 days) causes a significant and long-lasting reduction in PPD, an index that measures tissue destruction.AMY-101 (Cp40, 1 mg/kg, sc, injection every 12 h, daily, 7 or 14 days) attenuates fibrosis and infiltration of inflammatory cells in UUO-induced renal fibrosis.Animal Model:Fifteen adult male cynomolgus monkeys (Macaca fascicularis) (7-15 years old; 5.0-7.6 kg body weight).
Dosage:0.1 mg/site; 50 μL of 2 mg/mL solution.
Administration:Injected locally. (Either three times per week or once a week for 6 weeks followed by a 6-week follow-up period without treatment.)
Result:Does not cause irritation in healthy gingiva.
Animal Model:UUO and sham-operated mice.
Dosage:1 mg/kg.
Administration:Subcutaneous injection every 12 h, daily, 7 or 14 days.
Result:1 mg/kg Cp40 had much less severe interstitial fibrosis than control peptide-injected mice.
AMY-101 (Cp40), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation.
体内研究：
AMY-101 can improve the periodontal condition of NHPs with natural chronic periodontitis.AMY-101 can induce a long-lasting anti-inflammatory effect.AMY-101 (4 mg/kg bodyweight, subcutaneous injection. once per 24 hr for a total of 28 days) causes a significant and long-lasting reduction in PPD, an index that measures tissue destruction.AMY-101 (Cp40, 1 mg/kg, sc, injection every 12 h, daily, 7 or 14 days) attenuates fibrosis and infiltration of inflammatory cells in UUO-induced renal fibrosis.Animal Model:Fifteen adult male cynomolgus monkeys (Macaca fascicularis) (7-15 years old; 5.0-7.6 kg body weight).
Dosage:0.1 mg/site; 50 μL of 2 mg/mL solution.
Administration:Injected locally. (Either three times per week or once a week for 6 weeks followed by a 6-week follow-up period without treatment.)
Result:Does not cause irritation in healthy gingiva.
Animal Model:UUO and sham-operated mice.
Dosage:1 mg/kg.
Administration:Subcutaneous injection every 12 h, daily, 7 or 14 days.
Result:1 mg/kg Cp40 had much less severe interstitial fibrosis than control peptide-injected mice.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备